logo-loader
RNS
GSK PLC

GSK PLC - Directorate Change

RNS Number : 8765N
GSK PLC
27 September 2023
 

Issued: 27 September 2023, London UK

 

GSK announces Wendy Becker to join the Board as Non-Executive Director

 


GSK plc (LSE/NYSE: GSK) has today announced that Wendy Becker will join the Board of the Company as a Non-Executive Director with effect from 1 October 2023.

 

On joining the Board, Wendy will become a member of the Company's Remuneration Committee. She will succeed Urs Rohner as Chair of the Remuneration Committee after the Company's 2024 Annual General Meeting when Urs steps down on completion of his nine years' service to the Board.

 

Wendy is currently Chair of Logitech International S.A., and a Board member and Chair of the Compensation Committee of Sony Group Corporation.  She has strong executive management experience including senior roles at McKinsey & Company, TalkTalk, and Vodafone and as CEO at Jack Wills.  Within the life sciences sector, Wendy is a Board member and Chair of the Remuneration Committee of Oxford Nanopore Technologies plc. She is a member of the governing bodies of the University of Oxford and related subsidiaries.

 

Commenting on Wendy's appointment, Sir Jonathan Symonds, Chair of GSK said: "I am delighted to welcome Wendy to GSK. Wendy is a highly experienced non-executive director, and has held significant leadership positions in a wide range of global businesses, including several in the technology and life sciences sectors. I'm sure she will make a significant contribution to the Board and we look forward to her joining in October."


 

Notes:

 


1.   The appointment of Wendy Becker was made by the Board on the recommendation of the Nominations & Corporate Governance Committee. The Committee conducted an extensive search and selection process for this appointment, using an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms. The external search firm provided a diverse list of candidates who were approached, evaluated and interviewed, against an agreed set of criteria aligned to the Board's target skills matrix.  The Board satisfied itself that Ms Becker had the experience and time available to carry out the role.

 


2.   The Board has determined that Wendy Becker is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.

 


3.   Ms Becker will receive the standard basic fee for a Non-Executive Director of £113,800 per annum (including travel allowance).

 

She will receive fees of £40,000 per annum when she succeeds Mr Rohner as Chair of the Remuneration Committee.

 

Ms Becker will be required to build towards a share ownership requirement of GSK shares in accordance with the Company's shareholder approved Non-Executive remuneration policy. 

 


4.   Ms Becker will also become a member of the Audit & Risk Committee on her appointment.

 


5.   Ms Becker does not have a service contract. She has a letter of appointment which may be viewed by contacting the Company Secretary at the Company's registered office.

 


6.   There are no further disclosures to be made in respect of Ms Becker's appointment under Listing Rule 9.6.13R.

 


7.   As of 1 October 2023 the Board of GSK will comprise:

 

Sir Jonathan Symonds

Non-Executive Chair

Emma Walmsley

Chief Executive Officer

Julie Brown

Chief Financial Officer

Charles Bancroft

Senior Independent Non-Executive Director

Elizabeth McKee Anderson

Independent Non-Executive Director

Dr Hal Barron

Non-Executive Director

Dr Anne Beal

Independent Non-Executive Director

Wendy Becker

Independent Non-Executive Director

Dr Hal Dietz

Independent Non-Executive Director

Dr Jesse Goodman

Independent Non-Executive Director

Urs Rohner

Independent Non-Executive Director

Dr Vishal Sikka

Independent Non-Executive Director

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

GSK enquiries




Media:

Tim Foley

+44 (0) 20 8047 5502

(London)


Kathleen Quinn

+1 202 603 5003

(Washington DC)



 


Investor Relations:

Nick Stone

+44 (0) 7717 618834

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Mick Readey

+44 (0) 7990 339653

(London)


Josh Williams

+44 (0) 7385 415719

(London)


Camilla Campbell

+44 (0) 7803 050238

(London)


Steph Mountifield

+44 (0) 7796 707505

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)


Frannie DeFranco

+1 215 751 4855

(Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022, and Q2 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAXDLFLXKLFBBQ
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read